Investment Thesis
InfuSystem demonstrates solid gross margins (58.4%) and conservative leverage, but is hampered by anemic profitability (3% net margin) and critically weak cash generation ($813K FCF on $33.7M revenue). Returns on equity and assets are distressingly low (1.7% and 1.0%), indicating poor capital efficiency in a medical device sector that should deliver stronger operational performance.
Strengths
- Strong gross margin at 58.4% indicates solid pricing power and cost control at product level typical of medical devices
- Conservative capital structure with 0.33x debt-to-equity ratio and adequate interest coverage of 3.5x
- Solid liquidity position with 2.14x current ratio and 1.80x quick ratio providing financial flexibility
- Modest 6.4% revenue growth with improving EPS trajectory (+181.8% YoY)
Risks
- Critical cash generation weakness: only $970K operating cash flow on $33.7M revenue indicates operational inefficiency
- Minimal absolute profitability ($1.0M net income) and extremely low returns on capital (1.7% ROE, 1.0% ROA) suggest poor capital deployment
- Dangerously low cash balance ($2.1M) relative to $19.6M long-term debt creates refinancing risk in adverse conditions
- Thin operating margin (4.7%) leaves no room for error; vulnerable to cost pressures or competitive pricing
- Limited insider activity suggests potential lack of confidence in company trajectory
Key Metrics to Watch
- Operating cash flow trend - critical indicator of whether profitability translates to actual cash generation
- Gross margin sustainability - watch for erosion that would further compress already-thin net margins
- Net income growth trajectory - validate whether current profitability improvement is sustainable or one-time driven
- Cash balance and working capital - monitor for liquidity stress given low absolute cash levels
- Return on equity and assets - these must show meaningful improvement to justify continued investment
Financial Metrics
Revenue
33.7M
Net Income
1.0M
EPS (Diluted)
$0.05
Free Cash Flow
813.0K
Total Assets
98.7M
Cash
2.1M
Profitability Ratios
Gross Margin
58.4%
Operating Margin
4.7%
Net Margin
3.0%
ROE
1.7%
ROA
1.0%
FCF Margin
2.4%
Balance Sheet & Liquidity
Current Ratio
2.14x
Quick Ratio
1.80x
Debt/Equity
0.33x
Debt/Assets
40.5%
Interest Coverage
3.49x
Long-term Debt
19.6M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T11:12:35.044615 |
Data as of: 2026-03-31 |
Powered by Claude AI